(Press-News.org) A woman's race/ethnicity and socioeconomic status impact whether health care providers recommend one of the most highly effective forms of contraception, a UCSF study confirms. The results also indicate that the interaction of both factors plays a role in clinicians' decisions.
Recommendations by health care providers previously have been found to vary by patients' race and socioeconomic status, contributing to health disparities, according to the researchers. The team investigated the effect of these factors on recommendations for contraception.
Study results appear in the October print edition of the American Journal of Obstetrics and Gynecology and are available online at http://www.ajog.org/article/S0002-9378(10)00578-8/fulltext. An editorial commenting on the study also is included in the Journal.
In the study, clinicians' recommendations for intrauterine devices (IUDs), considered among the most effective forms of contraception, were affected by both the patient's class and her race/ethnicity.
Clinicians were less likely to recommend IUDs to white women of low socioeconomic status than to white women of high socioeconomic status.
Socioeconomic status had no significant effect on recommendations for IUDs for Latinas and black women.
But when the researchers evaluated the groups by race/ethnicity, clinicians were more likely to recommend IUDs to Latinas and black women of low socioeconomic status than to white women of low socioeconomic status.
"Understandably, people want simple answers but the complexity of the results is not surprising. We live in a complex world where race and class are intertwined, " said Christine Dehlendorf, MD, MAS, assistant professor in the UCSF Department of Family and Community Medicine and the UCSF Department of Obstetrics, Gynecology & Reproductive Sciences. "Clinicians need to be cognizant of how their patients' characteristics may influence the care they provide."
In the study, one of 18 videos depicting patients with varying socioeconomic and racial characteristics was shown to 524 healthcare providers, who then were asked whether they would recommend an IUD to the patient. The study group was drawn from medical physicians, osteopathic physicians, nurse practitioners and physician assistants who attended meetings of professional societies of family medicine and gynecology.
Previous research on the effect of patient race/ethnicity and class on clinicians' behaviors has focused on patient-provider interactions involving medical decisions about diseases, such as coronary artery disease, for which there is general consensus about appropriate treatments. Decisions about family planning, in contrast, involve multiple clinically appropriate options. The most effective choice may depend on a patient's personal preference, the team states.
"Providing contraceptive services is a particularly sensitive area of health care, both because of the intimate nature of the discussion of sexual behavior and because of the historical relationship of efforts to promote contraception with attempts to limit the fertility of minority and poor women in the United States," Dehlendorf said. "Family planning providers should work to ensure that they provide quality, patient-centered care to all women."
The inconsistency in health care provider recommendations for such an effective contraception method suggests a need for further research into the influence of clinicians' recommendations on family planning and ways to prevent the differences in care, she said.
The IUD, a small, plastic device that is inserted and left inside the uterus to prevent pregnancy, is more effective than most other forms of birth control, according to the American Congress of Obstetricians and Gynecologists.
"This is an especially important area of research given the high rate of unintended pregnancy in the US. It is critical that we provide comprehensive contraceptive counseling and equitable access to highly effective long-acting reversible contraceptives such as the IUD to all women," said Jody Steinauer, MD, MAS, senior study author and associate professor in the UCSF Department of Obstetrics, Gynecology and Reproductive Sciences.
###
Co-authors are Rachel Ruskin, MD, of the UCSF Department of Obstetrics, Gynecology and Reproductive Sciences; Kevin Grumbach, MD, of the UCSF Department of Family and Community Medicine; Eric Vittinghoff, PhD, of the UCSF Department of Epidemiology and Biostatistics; Kirsten Bibbins-Domingo, MD, PhD, of the UCSF Department of Epidemiology and Biostatistics and UCSF Department of Medicine; and Dean Schillinger, MD, of the UCSF Department of Medicine.
The study was funded by the Fellowship in Family Planning and by the National Institutes of Health.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
Follow UCSF on Twitter at http://twitter.com/ucsf
END
When people are rejected by peers, they often lash out. In children, that aggression occasionally takes horrifying directions, leading to school shootings or other deadly acts. Researchers in the Netherlands found that some children are more likely than others to lash out in response to acute peer rejection: children who already feel like outcasts.
"It was inspired by the fact that we had these school shootings and wondered what the most important feature of these kids could be," says Albert Reijntjes of Utrecht University, who cowrote the study with five other psychological ...
RICHMOND, Va. (Oct. 8, 2010) – An international team of researchers has discovered a new class of highly electronegative chemical species called hyperhalogens, which use superhalogens as building blocks around a metal atom. The new chemical species may have application in many industries.
Researchers from Virginia Commonwealth University, McNeese State University in Lake Charles, La., and the University of Konstanz in Germany report their discovery in the Oct. 6 international chemistry journal Angewandte Chemie International Edition. The journal designated the paper as ...
At 11 a.m. EDT on Oct. 8, Otto strengthened into a hurricane, becoming the eighth hurricane of the Atlantic Ocean season. NASA's Aqua satellite and the NOAA GOES-13 satellite captured images of Otto as he intensified.
Otto had maximum sustained winds near 75 mph, and the National Hurricane Center in Miami, Fla. noted that some strengthening is possible before it weakens on Saturday, Oct. 9. Otto was located about 445 miles south of Bermuda near 25.9 North and 64.0 West. It was moving east-northeast near 17 mph, and had a minimum central pressure of 979 millibars.
On ...
The Sample Analysis at Mars (SAM) instrument suite has completed assembly at NASA's Goddard Space Flight Center in Greenbelt, Md., and is nearly ready for a December delivery to NASA's Jet Propulsion Laboratory (JPL), Pasadena, Calif., where it will be joined to the Curiosity rover. SAM and Curiosity are set to fly on the on the upcoming Mars Science Laboratory (MSL) rover mission scheduled for launch in the fall of 2011.
SAM will become an automated, mobile laboratory as it is carried across Mars by the rover when the mission arrives at the Red Planet in 2012. Together ...
DALLAS – Oct. 12, 2010 – Researchers at UT Southwestern Medical Center have created an experimental vaccine against beta-amyloid, the small protein that forms plaques in the brain and is believed to contribute to the development of Alzheimer's disease.
Compared with similar so-called DNA vaccines that the UT Southwestern researchers tested in an animal study, the new experimental vaccine stimulated more than 10 times as many antibodies that bind to and eliminate beta-amyloid. The results appeared in the journal Vaccine.
Future studies will focus on determining the ...
Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets.
The study is published in the Oct. 8 issue of the Journal of Biological Chemistry, where it is designated a paper of the week.
Approximately 70 percent of breast cancers express the estrogen receptor. These "ER-positive" tumors usually respond to hormone-related therapies, such as tamoxifen or aromatase inhibitors. But not always.
"We ...
WASHINGTON, Oct. 9, 2010 — Help may be on the way for millions of people on the East Coast bugged out about the invasion of stink bugs. Scientists have reported a key advance in efforts to develop the first commercial repellent for stinkbugs, which are emerging as a major nuisance to homeowners and a devastating pest to some farm crops. They identified a natural substance in a fungus that infects a common weed and found that it shows potential as the first stinkbug repellent. Their study appeared in ACS' bi-weekly Journal of Agricultural and Food Chemistry.
Hiromitsu ...
CHICAGO -- Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online today by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles will appear in the October 27 print issue of JAMA.
According to background information in the papers, obesity is among the ...
In another article being released early online, Cheryl L. Rock, Ph.D., R.D., from Moores UCSD Cancer Center, La Jolla, Calif., and colleagues, conducted a randomized controlled trial of weight loss and weight maintenance in 442 overweight or obese women (BMI, 25 – 40), ages 18 to 69, over a two year period with follow-up between November 2007 and April 2010.
The women were randomized into three intervention groups: in-person, center-based (167 women) or telephone based (164 women) weekly one-to-one weight loss counseling, including free-of-charge prepackaged prepared ...
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
Dr David Spigel, Director of lung cancer research for the Sarah Cannon Research Institute in Nashville, Tennessee reported the trial findings at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
The study included 128 patients with advanced non-small cell lung cancer who were ...
